We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AB SCIEX, Dalton Pharma Services Announce ADC Partnership
News

AB SCIEX, Dalton Pharma Services Announce ADC Partnership

AB SCIEX, Dalton Pharma Services Announce ADC Partnership
News

AB SCIEX, Dalton Pharma Services Announce ADC Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AB SCIEX, Dalton Pharma Services Announce ADC Partnership "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The partnership will include development of more definitive and comprehensive methods for the identification of drug loading and position of conjugation on macromolecules. This collaboration is part of AB SCIEX's commitment to support the growing movement to bring targeted antibody-based therapies to market.

Our collective goal is to help our customers bring drugs from concept to market faster. The collaboration provides AB SCIEX, a global leader in life science analytical technologies, with the specialized synthetic conjugation capabilities of Dalton. The research includes the preparation and characterization of ADC’s by Dalton scientists working with AB SCIEX experts to develop standardized analytical procedures on the TripleTOF® 5600+ system with SelexION™ technology and the new TripleTOF® 6600 platform for determining the chemical structures of conjugated molecules.

"A key challenge for developing successful Antibody-Drug Conjugate medicines is understanding the structure and payload of the final molecule. Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC," explained Tan Quach, Chemistry Manager at Dalton Pharma Services.

"Recent advances in mass spectrometry have provided a solution to answer the challenging questions in terms of understanding ADC drug development and working within a biological matrix,” said Chris Radloff, Vice President, LC/ MS Business at AB SCIEX.  “Utilizing these molecules is difficult and by forming this partnership, ADC developers can now reduce complications, and obtain accurate results that will ultimately lead to safer, more effective therapies.”

Results of the first phase of the collaboration were featured at ASMS 2014 in Baltimore. The partnership will continue to co-develop standardized analytical procedures using the MS technology, which delivers more consistent results than platforms such as ELISA. The partnership will also aim to publish technical papers over the coming months.

Advertisement